Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation  by Calvo-Pinilla, Eva et al.
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In previous  studies  we showed  that  a  recombinant  Modiﬁed  Vaccinia  Ankara  (MVA)  virus  expressing
the  protein  VP2  of  AHSV  serotype  4 (MVA-VP2)  induced  virus  neutralising  antibodies  in horses  and
protected  interferon  alpha  receptor  gene  knock-out  mice  (IFNAR−/−)  against  challenge.  We  continued
these  studies  and  determined,  in the  IFNAR−/−  mouse  model,  whether  the antibody  responses  induced  by
MVA-VP2  vaccination  play  a key  role  in protection  against  AHSV.  Thus,  groups  of  mice  were  vaccinated
with  wild  type  MVA  (MVA-wt)  or MVA-VP2  and  the  antisera  from  these  mice  were  used  in a  passive
immunisation  experiment.  Donor  antisera  from  (a)  MVA-wt;  (b)  MVA-VP2  vaccinated;  or  (c) MVA-VP2
vaccinated  and AHSV  infected  mice,  were  transferred  to AHSV  non-immune  recipient  mice.  The  recipients
were  challenged  with  virulent  AHSV  together  with  MVA-VP2  vaccinated  and  MVA-wt  vaccinated  controlVA-VP2
rotection
umoral response
assive immunisation
animals  and  the  levels  of  protection  against  AHSV-4  were  compared  between  all  these  groups.  The  results
showed that  following  AHSV  challenge,  mice  that  were  passively  immunised  with  MVA-VP2  vaccinated
antisera  were  highly  protected  against  AHSV  disease  and  had  lower  levels  of  viraemia  than  recipients  of
MVA-wt antisera.
Our  study  indicates  that  MVA-VP2  vaccination  induces  a highly  protective  humoral  immune  response
against  AHSV.
 2013©
. Introduction
African horse sickness (AHS) is an arthropod-borne viral disease
f solipeds transmitted by haematophagus insects of the genus Culi-
oides,  the horse being the most severely affected species. Mortality
ates of AHSV outbreaks in immunologically naïve populations may
xceed 90% (Mellor and Hamblin, 2004).
AHSV is a member of the genus Orbivirus, family Reoviridae,
nd is closely related to the virus causing bluetongue in rumi-
ants. The non-enveloped 55–70 nm AHSV spherical virion capsid
s composed of three concentric layers (Roy et al., 1994). The outer
apsid is formed by two major structural proteins, VP2 and VP5
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(encoded by segments 2 and 6, respectively), involved in cell attach-
ment and cell entry. VP2 is the most variable antigen of AHSV and
is responsible for serotype formation (Burrage et al., 1993). The
outer capsid rests on the outer core layer formed by the segment 8
encoded protein VP7. This is a highly hydrophobic protein and an
antigenically conserved major antigen of AHSV that forms the basis
of ELISA-based serological diagnostic tests. The inner core is formed
by VP3, encoded by segment 3, an antigenically conserved protein
providing the icosahedral framework of the virion. The inner core
encloses VP1, VP4 and VP6 proteins, (encoded by segments 1, 4 and
5, respectively) comprising the viral replicase complex and the 10
double-stranded RNA genome segments. There are four nonstruc-
tural proteins (NS1, NS2, NS3/3A, and NS4), involved in virus and
morphogenesis (Belhouchet et al., 2011; Manole et al., 2012; Roy
et al., 1994; van Staden et al., 1991).
Open access under CC BY-NC-ND license.AHSV infection in horses most often results in severe clinical dis-
ease and death but those animals that survive exhibit a solid lifelong
serotype-speciﬁc immunity. The humoral nature of AHS immu-
nity has been associated with virus neutralizing antibodies (VNAb)
 license.
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n passive immunisation experiments carried out in both horses
nd mice using colostrum and monoclonal antibodies, respectively
Blackburn and Swanepoel, 1988; Burrage et al., 1993). Consistent
ith this, vaccination and challenge experiments demonstrated a
orrelation between the presence of VNAb in serumand protec-
ion. The main target of VNAb is AHSV VP2 (Burrage et al., 1993)
nd several studies mapped neutralising epitopes to the ﬁrst half
f the VP2 protein (Bentley et al., 2000). AHSV VP5 appears to be
nvolved in formation of virus neutralising epitopes by inﬂuencing
he conformation of VP2 (Martinez-Torrecuadrada et al., 1996).
Only very recently, information about cell-mediated immunity
gainst AHSV has become available. Studies by Pretorius et al.
2012) demonstrated an in vitro recall cellular immune response
n peripheral blood mononuclear cells (PBMC) of horses vacci-
ated with live-attenuated AHSV vaccines and El Garch et al. (2012)
howed IFN- CD8+ T-cell responses in PBMC collected from horses
accinated with a recombinant Canarypox virus co-expressing both
P2 and VP5 of AHSV-4. More recently, cell-mediated immune
eponses have also been observed in interferon alpha receptor gene
nock-out mice (IFNAR−/−) after vaccination with MVA  VP2/NS1
de la Poza et al., 2013). Since cellular immunity has been associ-
ted with protection in bluetongue, it is generally assumed that the
ame applies to AHS.
Control of AHSV in endemic countries is primarily based on
accination. Live-attenuated AHSV vaccines have been in use,
ith relative success, for more than ﬁve decades. However, con-
erns about reversion to virulence, gene segment re-assortment
etween outbreak and vaccine strains and the lack of a differential
iagnostic test makes the use of attenuated vaccines undesirable
or non-endemic countries. Consequently, AHSV vaccine research
ocused in recent years on the development of DIVA (Differentiat-
ng Infected from Vaccinated Animals) vaccines based on selected
roteins of the AHSV antigenic repertoire, in particular the cap-
id proteins. Thus, baculovirus expression systems, plasmid DNA
nd viral vector vaccines have all been used to induce protective
mmunity using any combination of VP2, VP5, VP7, NS1 and VP3
ntigens (de la Poza et al., 2013; Guthrie et al., 2009; Martinez-
orrecuadrada et al., 1996; Roy et al., 1996).
Recently, we have shown that vaccination of ponies with a
ecombinant modiﬁed Vaccinia Ankara (MVA) virus expressing VP2
f AHSV serotype 4 (MVA-VP2) induced VNAb (Chiam et al., 2009).
n a follow up study, vaccination of IFNAR−/− mice with MVA-
P2 induced VNAb and complete protection upon challenge with
 virulent AHSV-4 (Castillo-Olivares et al., 2011). Since viral vec-
ors in general, and MVA  in particular, are capable of inducing
oth humoral and cell-mediated immunity, we began to investigate
hether the protective immunity against AHSV induced by MVA-
P2 vaccination is mediated by either of these effector mechanisms
f immunity. In this study we evaluated the protective capacity
gainst AHSV of MVA-VP2 vaccine-induced antibodies in a passive
mmunisation experiment. We  have demonstrated that MVA-VP2
accination induces a highly protective humoral immune response.
. Materials and methods
.1. Viruses and cells
Chicken embryo ﬁbroblast (DF-1) (ATCC, Cat. No. CRL-12203)
nd Vero cells (ATCC, Cat. No. CCL-81) were grown in Dulbecco’s
odiﬁed Eagle’s medium (DMEM) supplemented with 2 mM glu-
amine, penicillin (100 units/ml), streptomycin (100 g/ml) and
0% fetal calf serum (FCS). AHSV serotype 4 (Madrid/87) (AHSV-4)
as grown in Vero cells and MVA  viruses grown in DF-1 cells. Virus
tocks were generated by infection of conﬂuent cells using a mul-
iplicity of infection (MOI) of 0.1. At 48 h post-infection, or when a
otal cytopathic effect (CPE) was visible, the cells and supernatantssearch 180 (2014) 23– 30
were harvested and centrifuged. The virus was  released from the
cells by three freeze and thaw cycles and then titrated by plaque
assay. The MVA  VP2 virus used in this work has been previously
described (Chiam et al., 2009).
2.2. Mice
IFN / Ro/o IFNAR−/− mice on a 129 background were pur-
chased from B&K Universal Ltd (UK). Eight-week old mice were
used throughout. Mice were maintained under pathogen-free con-
ditions and allowed to acclimatize to the biosafety level 3 (BSL3)
animal facilities at the Centro de Investigacion en Sanidad Animal,
INIA, Madrid (CISA-INIA), for 1 week before use. All experiments
with live animals were performed under the guidelines of the Euro-
pean Community (86/609) and were approved by the ethical review
committee of CISA-INIA (CEEA 2010-034).
2.3. Murine immunisations with MVA-VP2 and MVA-wt and
preparation of donor antisera (Stage 1)
Mice were randomly divided in four groups of six animals at the
start of the experiments (Table 1). Vaccinations were performed on
days 0 and 21 by administering, by the intraperitoneal route, two
doses of 107 pfu of MVA-VP2 (groups 1 and 2) or MVA-wt (groups
3 and 4). Two weeks after the second vaccination, groups 2 and
4 were euthanized by anaesthesia with 5% isoﬂurane followed by
cervical dislocation, and splenocytes and blood samples collected
from these animals. The blood was used to prepare donor antisera.
Also, at two weeks after the second vaccination, groups 1 and 3 were
challenged by subcutaneous inoculation of 106 pfu/mouse of AHSV-
4. Clinical signs and viraemia were evaluated from these animals.
All mice from group 1 survived the challenge and blood from these
animals was also used to prepare donor antisera. All donor antisera
were prepared by pooling individual sera from mice of the same
group. Thus, antisera D1, D2 and D4 were obtained from groups 1,
2 and 4, respectively.
2.4. Passive immunisation with donor antisera (Stage 2)
The donor antisera were inactivated (30 min  at 56 ◦C) and 100 l
used for intra-peritoneal injection of 4 groups of 10-week-old
recipient IFNAR−/− mice: (a) group 5, received undiluted D2 anti-
serum; (b) group 6 received D2 antiserum diluted 1 in 10; (c) group7
received undiluted D1 antiserum; and (d) group 8 received D4 anti-
serum. One hour following transfer, all recipient mice were infected
with a dose of 106 pfu of AHSV-4 administered subcutaneously. An
MVA-VP2 vaccinated control group (group 9) and an MVA-wt vacci-
nated negative control group (group 10) were infected at the same
time as the recipients (Table 2). Clinical signs and viraemia were
evaluated in all the animals.
2.5. Evaluation of clinical signs after challenge with AHSV-4
Following sub-cutaneous injection of 106 pfu of AHSV-4 ani-
mals were monitored twice daily from the start of the experiment
and more regularly (at least three times per day) at the onset of
any signs of morbidity. These included: changes in behaviour and
activity, changes in water or food intake, alterations in the hair
coat appearance, body weight loss, presence of ocular signs (con-
junctivitis, ocular discharge, swelling), changes in hydration and
presence of neurological signs (i.e. paresis, paralysis, ataxia). The
humane end-points for euthanasia included: persistent hunching,
severe conjunctivitis, signs of dehydration, loss of more than 20% of
body weight, presence of any neurological signs, or any other con-
dition that prevented food or water intake. Animals that displayed
E. Calvo-Pinilla et al. / Virus Research 180 (2014) 23– 30 25
Table  1
Stage 1: Preparation of donor antisera.
Groups Day 0 Day 21 Day 35 Day 50
1 MVA-VP2, 107 pfu/mouse MVA-VP2107 pfu/mouse Challenge AHSV-4106 pfu s-c* Collection of serum (D1)
2  MVA-VP2, 107 pfu/mouse MVA-VP2107 pfu/mouse Collection of serum (D2) and spleen
3  MVA-wt, 107 pfu/mouse MVA-wt107 pfu/mouse Challenge AHSV-4106 pfu s-c.
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 Sub-cutaneous.
ny of these clinical signs were humanely euthanized by cervical
islocation following anaesthesia with 5% isoﬂurane.
.6. Virus neutralisation test
Serum samples from mice were heat-inactivated for 30 min at
6 ◦C and two-fold serial dilutions were incubated with 100 TCID50
f AHSV-4 in triplicate wells of 96-well microtitre plates for 1 h
nd then overnight at 4 ◦C. The following day, 2 × 104 Vero cells
ere added to each well and incubated for 3 days at 37 ◦C, 5% CO2.
he plates were checked for AHSV cytopathic effect, with the end-
oint of the assay been taken as the highest dilution that prevented
HSV cytopathic effect in 50% of the wells. Antibody titres were
hen calculated by the Karber (1931) formula and expressed in log10
nits.
.7. VP2-speciﬁc antibody detection by indirect enzyme-linked
mmunosorbent assay (ELISA)
Brieﬂy, 96-well polystyrene plates (Nunc) were coated
vernight with 160 ng/well of recombinant AHSV-4-VP2 expressed
n a baculovirus expression system. Plates were washed four times
ith PBS with 0.05% Tween 20 and blocked with 5% milk diluted
n PBS for 1 h at room temperature. Serum samples were diluted
:50 in PBS 2.5% milk and allowed to incubate for 1 h at 37 ◦C.
lates were washed four times, and a horseradish peroxidase (HRP)
onjugated rabbit antibody against total mouse immunoglobulins
Southern Biotech) was  diluted (1:2000) in blocking buffer and
dded to plates. Plates were incubated for 1 h at 37 ◦C, washed
our times and a colorimetric reaction developed after addition of
00 l of TMB  substrate (Sigma-Aldrich). Plates were incubated
n the dark for 30 min, and the reaction was stopped with 2 N
SO . Optical densities at a wavelength of 450 nm (OD 450) were2 4
ead by a spectrophotometer (BioTek). The cut-off point between
 positive and a negative result was set at an optical density of
.2.
able 2
hase II: Passive immunisation and challenge.
Groups Treatment Challenge AHSV-4
5 Immunised with D2 antiserum
Undiluted, intra-peritoneal,
100 l
1 h after transfer (day 35)
106 pfu sub-cutaneous
6  Immunised with D2 antiserum
Diluted 1 in 10,
intra-peritoneal, 100 l
1 h after transfer (day 35)
106 pfu sub-cutaneous
7  Immunised with D1 antiserum
Undiluted, intra-peritoneal,
100 l
1 h after transfer (day 35)
106 pfu sub-cutaneous
8  Immunised with D4 antiserum
Undiluted, intra-peritoneal,
100 l
1 h after transfer (day 35)
106 pfu sub-cutaneous
9  Vaccinated MVA-VP2
Day 0 prime, Day 21 boost
Day 35 post MVA-VP2 prime
106 pfu sub-cutaneous
10  Vaccinated MVA-wt
Day 0 prime, Day 21 boost
Day 35 post MVA-wt prime
106 pfu sub-cutaneousCollection of serum (D4) and spleen
2.8. Detection of AHSV-4 in blood
Whole blood from animals was collected in EDTA at regular
intervals after inoculation for virus isolation. Volumes of 200 l of
blood were washed in PBS, mixed with 900 ml of water to lyse the
cells and then 100 l of 10× PBS was added to the sample. The
amount of infectious virus was  measured by standard plaque assay
on Vero cells.
2.9. Isolation of splenocytes and antigen stimulation
Vaccinated mice were euthanized and their spleens asepti-
cally collected. Spleen cells were then released into RPMI media
by mashing the organs and ﬁltering through 70 m cell strainers
(Falcon). After red blood cell lysis with NH4Cl (0.83%), spleno-
cytes were re-suspended in complete RPMI media supplemented
with 10% fetal bovine serum, 1% penicillin-streptomycin, 1% l-
glutamine. Cells were stimulated with an AHSV-4 infected Vero cell
extract that had been inactivated by a 30 min exposure to ultravi-
olet light (400 J/cm2). The effectiveness of virus inactivation was
conﬁrmed by failure of the extract to infect cell monolayers in a
standard plaque assay. Positive control cells were stimulated with
PMA/Ionomycin (Sigma–Aldrich) (PMA at 100 ng/ml; Ionomycin at
12.5 M),  and negative control cells with an uninfected Vero cell
extract. After 66 h of incubation, extracellular protein transport was
inhibited by the addition of brefeldin A (Invitrogen) at a dilution of
1/1000 in RPMI complete medium. Cells were further incubated for
6 h more before staining.
2.10. Flow cytometry for intracellular IFN- detection
Following antigen stimulation, cells were recovered to perform
surface staining with FITC-labelled anti-CD4 and PErCP-labelled
anti-CD8 antibodies (Ebioscience). Subsequently, permeabilizing
buffer was  added (PBS 0.02% saponin 4% FBS) and intracellular
staining with PE-labelled anti-IFN- was performed. Finally cells
were ﬁxed in 4% paraformaldehyde in phosphate-buffered saline
for ﬂow cytometric analysis.
The analysis was  performed using a FACSCalibur ﬂow cytometer
(BD Biosciences, France) and analysis was done using CellQuest Pro
software. The percentage of antigen speciﬁc IFN- producing cells
of each mouse was  calculated as the percentage of IFN- producing
cells obtained with virus stimulation minus the percentage of IFN-
producing cells obtained with cellular extract stimulation.
2.11. Statistical methods
Survival: Survival data (days post infection at which each mouse
died) were analysed using a log rank test with mice grouped by
immunisation strategy. Mice which survived the experiment were
right-censored.CD8+ T cells producing IFN-: The proportion of CD8+ T cells
producing IFN- derived from vaccinated and unvaccinated mice
(measured as the percentage of cells producing IFN- following
virus stimulation minus the percentage of cells producing IFN-
2 rus Research 180 (2014) 23– 30
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Fig. 1. Survival rates and viraemia after challlenge with AHSV-4. MVA-VP2 vac-
cinated mice (group 1) and MVA-wt vaccinated (group 3) were challenged with
106 pfu of AHSV-4 35 days post-vaccination. (A) Survival rates, expressed as per-
viral antibodies by virus neutralisation test and VP2-speciﬁc ELISA.
The results are summarised in Table 3. Mean VNAb titres were
1.9 ± 0.164 in MVA-VP2 vaccinated animals, whilst antisera from
MVA-wt vaccinated mice did not neutralise the virus. The results
Table 3
Results of VN test and ELISA of serum samples collected from mice groups 1–4 on
day  35 post-vaccination during the Phase I of the study.
Groups log10 VNT50 OD  ELISA VP26 E. Calvo-Pinilla et al. / Vi
ollowing stimulation with cell extract; see Section 2.10) was com-
ared using a Wilcoxon rank-sum test.
Viraemia: Data on viraemia were analysed using a linear mixed
odel with log10 (pfu/ml + 1) as the response variable, immunisa-
ion strategy and days post infection (as a factor) as ﬁxed effects and
ouse as a random effect. Model selection proceeded by stepwise
eletion of non-signiﬁcant terms (as judged by the Akaike informa-
ion criterion (AIC), with a difference in AIC of two or more taken
o indicate signiﬁcance), starting from an initial model includ-
ng immunisation strategy and days post infection. Once the ﬁnal
odel had been constructed, post hoc Tukey tests were used to
dentify signiﬁcant (P < 0.05) differences between factor levels.
Virus neutralisation: Virus neutralising antibody titres at 17 days
ost infection were compared using a linear model with log10
itre as the dependent variable and immunisation strategy as a
xed effect. Post hoc Tukey tests were used to identify signiﬁcant
P < 0.05) differences between factor levels.
All analyses were implemented in R (R-Core-Team, 2012).
. Results
To investigate the protective role of the antibody response
nduced by MVA-VP2 vaccination against AHSV, a passive immun-
sation study was conducted whereby antiserum from MVA-VP2
accinated mice was transferred to recipient mice that were sub-
equently challenged with AHSV-4. We  conducted this study in
wo stages: (1) determination of protective immunity of MVA-VP2
accination and preparation of donor antisera; and (2) determina-
ion of protective immunity following passive immunisation with
VA-VP2 vaccination-induced antisera.
.1. Determination of MVA-VP2 protective immunity and
reparation of donor antisera (Stage 1)
To test the protective capacity of antisera from MVA-VP2 vac-
inated mice it was necessary ﬁrst to conﬁrm that the MVA-VP2
accination protocol used induced protective immunity against
HSV-4. Thus, MVA-VP2 vaccinated and MVA-wt vaccinated mice
groups 1 and 3, respectively) were challenged with AHSV-4 and
linical signs and viraemia evaluated. In parallel, groups 2 (MVA-
P2) and 4 (MVA-wt), vaccinated in exactly the same manner as
roups 1 and 3, were used for preparation of donor D2 and D4 anti-
era. Surviving mice from group 1 were the source of a positive
ontrol donor antiserum D1.
.1.1. Protective immunity of MVA-VP2 vaccination against
HSV-4 challenge (groups 1 and 3)
Following AHSV-4 infection, 3 mice from group 3 developed
linical signs such as weight loss, dehydration, rufﬂed hair, ocu-
ar discharges, periorbital swelling and ataxia and were euthanized
etween 6 and 10 days post-infection according to the humane end-
oints described in Materials and Methods. Two mice displayed
linical signs but did not surpass the severity limit of the experi-
ent and ﬁnally recovered by day 14 post-infection. The animals in
his group were viraemic and the percentage of survival in the MVA-
t vaccinated mice following challenge was 33.33%. In contrast, all
VA-VP2 vaccinated animals (group 1) remained clinically normal
hroughout the study (Fig. 1). Furthermore, survival times differed
igniﬁcantly between the two groups (log rank test: 2 = 5.5 df = 1;
 = 0.02) (Fig. 1). No infectious virus was isolated from MVA-VP2
accinated animals. In contrast, MVA-wt mice presented viraemia
or a number of days and peaked at day 5 post-infection with a
ean value of 1358 ± 458 pfu/ml. All these data indicated that vac-
ination with MVA-VP2 completely protected IFNAR−/− mice in
his experiment and is consistent with our previous observations
Castillo-Olivares et al., 2011).centage of survival, of groups 1 and 3. (B) Viral titres of groups 1 and 3. Blood samples
were obtained from the mice, processed and titrated using a standard virus plaque
assay.
The donor antiserum D2, obtained from MVA-VP2 vaccinated
mice (group 2), was  derived from animals that had the same vacci-
nation regime as those that were immune to AHSV-4 (group 1). This
antiserum is therefore adequate to address the question of whether
antibody responses induced by MVA-VP2 vaccination played a role
in protection. Group 3 mice, vaccinated with MVA-wt were fully
susceptible to AHSV-4 infection. Therefore, antiserum D4, obtained
also from MVA-wt vaccinated mice was adequate as a negative con-
trol donor antiserum. The positive control donor antiserum D1 was
collected from group 1 mice (MVA-VP2 vaccinated) 15 days after
they had survived challenge with AHSV-4.
3.1.2. Antibody responses following immunization with MVA-VP2
(groups 1–4)
Serum samples were collected at 35 days post-vaccination (at
the time of challenge) from mouse groups 1–4 and analysed for1 1.9 ± 0.164 1.574 ± 0.334
2  1.9 ± 0.154 1.666 ± 0.222
3  – 0.122 ± 0.029
4  – 0.107 ± 0.035
E. Calvo-Pinilla et al. / Virus Re
Fig. 2. IFN- gamma producing cells. AHSV-4 speciﬁc IFN- CD8+ T-cell responses
of  individual MVA-VP2 vaccinated mice (group 2, V7-V12) and MVA-wt vaccinated
mice (group 4, C7-C12) was  analyzed by ﬂow cytometry at 35 days post-vaccination.
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ated with cell extract. Grey bars represent the percentages of IFN- CD8+ T-cells of
plenocytes stimulated with AHSV-4 antigen.
f the ELISA test showed that only vaccinated mice (groups 1 and
) showed speciﬁc antibodies against VP2 with a mean OD value of
.574 ± 0.334 (Table 3).
.1.3. Recall cell-mediated immune responses measured by
ntracellular IFN- staining in MVA-VP2 (group 2) and MVA-wt
group 4) vaccinates
Splenocytes from donor mice were isolated to perform intra-
ellular cytokine staining of IFN- in T-lymphocytes. The results
f these experiments are depicted in Fig. 2. In MVA-VP2 vac-
inated mice, the average percentage of antigen-speciﬁc CD8+
FN- responder cells (measured as the difference between bars in
ig. 2) was 1.01 ± 0.27%. In contrast, the average was  0.12 ± 0.06%
n MVA-wt mice (Wilcoxon rank-sum test: P = 0.002). No signiﬁ-
ant difference in the expression of IFN- by CD4+ T cells upon
e-stimulation in immunised mice (0.15 ± 0.21%) was observed
ompared with control mice (0.33 ± 0.15%). The difference in
HSV-speciﬁc IFN- response from CD8+cells between MVA-VP2
accinated and MVA-wt control mice indicated that vaccination
ith MVA-VP2 primes CD8+ T-lymphocytes thereby activating
nti-AHSV-4 CD8+ T cell responses.
.1.4. VP2-speciﬁc reactivity and neutralising antibody titres of
onor antisera
The reactivity by the VP2-speciﬁc ELISA and VNAb titres of the
ntisera (D1, D2 and D4) used for passive immunisation was deter-
ined. Antiserum D1, had an OD value of 2.69 by the VP2 ELISA
nd a VNAb titre of 2.51 (log10) whereas antiserum D2 had an O.D.
alue of 1.58 in the VP2 ELISA and a VNAb titre of 1.95 (log10). As
xpected, D4 was negative by both assays.
.2. Passive immunisation and AHSV-4 challenge (Stage 2)
To interrogate the protective capacity against AHSV-4 of anti-
odies induced by MVA-VP2 vaccination passive immunisation
ith antisera was undertaken as indicated in Section 2.4.
.2.1. Clinical signs, survival and viraemia of groups 5–10 after
HSV-4 challenge
The results of the AHSV-4 challenge of groups 5–10 are depicted
n Figs. 3 and 4. By day 3 after AHSV-4 infection, MVA-wt vaccinated
ice (group 10) and mice immunised with antiserum D4 (group
) started to develop clinical signs. These were weight loss, dehy-
ration, ocular discharges, periorbital swelling, and in some cases,search 180 (2014) 23– 30 27
ataxia and paresis in the hind limbs. All mice from group 10 and
4 from group 8 were euthanized between days 5 to 11. High viral
loads were detected in mice from both groups 8 and 10, reaching
maximum values before death. Even at day 3 post-challenge viral
titres up to 900 pfu/ml were detected in mice from group 10. In
contrast and as expected, MVA-VP2 vaccinated animals (group 9)
remained completely healthy and had no detectable viraemia until
the end of the experiment.
Protection against AHSV-4 challenge in groups immunised with
antisera D2 (group 5), D2 (diluted) (group 6) and D1  (group 7) var-
ied. Protection was  high for groups 5 and 7 and partial for group 6.
Thus, all mice in group 5 survived the challenge and showed min-
imal clinical signs (one individual showed rufﬂed hair and ocular
discharge). In addition, no infectious virus was  isolated from any
mouse in the group at day 3 post-infection and although viraemia
was found on following days, it was low and the virus was  ﬁnally
cleared. Similarly, mice from group 7 were completely protected
against AHSV challenge. The levels of viraemia in these animals
were similar to those in group 5, but virus was cleared earlier in
some mice from group 7. In comparison to the control groups (8
and 10) the course of disease was  slightly delayed in mice from
group 6 but 50% of the animals did have to be euthanised by day
11. Viraemia data for group 6 showed that virus titres were higher
and viraemia lasted longer than in groups 5 and 7.
The levels of viraemia seen at all time points differed signiﬁ-
cantly (P < 0.01) amongst groups of mice, and the groups could be
divided into those that had high (groups 8 and 10), intermediate
(groups 5–7) and low (group 9) levels of viraemia. The highest virus
titres were observed in mice which were either MVA-wt vaccinated
(group 10) or which received antiserum D4 (group 8). Intermediate
titres were observed in mice which received antisera D2 (undiluted
or diluted) or D1 (groups 5–7). The lowest titres of viraemia were
found in mice vaccinated with MVA  VP2 (group 9) (no viraemia).
Moreover, there were signiﬁcant (log rank test: 2 = 40.3, df = 5;
P < 0.001) differences in survival times for mice immunised accord-
ing to different strategies (Fig. 4). In particular, survival was lowest
in mice which received antiserum D4 (group 8) or which were vac-
cinated with MVA-wt (group 10), and was intermediate in mice
which received antiserum D2 (diluted) (group 6).
These results indicate that the protection against AHSV induced
by MVA-VP2 vaccination is mediated primarily by antibodies and
that the level of protection observed correlated with antibody titre.
However, it is also probable that other effector mechanisms of
immunity induced by MVA-VP2 vaccination are important in pro-
tection against AHSV, since MVA-VP2 vaccinated mice (group 9)
were better protected than any of the passively immunised groups.
3.2.2. Antibody responses of groups 5–10
Serum samples were collected from all animals of groups 5–10
immediately before and 17 days after challenge with AHSV and
VNAb and AHSV-4-VP2-speciﬁc antibody responses were analysed
(Fig. 5). Only MVA-VP2 vaccinated mice (group 9) were positive
for VNAb prior to challenge. At 17 days post-challenge the levels of
VNAb differed signiﬁcantly (P < 0.001) amongst the different animal
groups. The highest titres were recorded in mice vaccinated with
MVA-VP2 (group 9) (log VNT = 3.13 ± 0.132). Intermediate titres
were observed in D2 (undiluted or diluted) or D1 recipients (groups
5–7). The lowest VNAb titres were observed in mice that received
antiserum D4 (group 8) (log VNT = 2.55).
The AHSV-4-VP2-speciﬁc antibody responses were determined
by ELISA using pools of sera from each group of mice (Fig. 5B).
All samples were negative at the time of challenge, except for
those from MVA-VP2 vaccinates (group 9). By day 10 post-infection
maximum levels of VP2-speciﬁc antibodies were detected in all
groups.
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Fig. 3. Passive immunisation and AHSV-4 challenge. Survival. Each panel corresponds to a different mouse group (groups 5–10) and shows the survival curves, expressed
as  a percentage of surviving mice per day, for each individual group of mice.
Fig. 4. Passive immunisation and AHSV-4 challenge. Viraemia. Each panel corresponds to a different mouse group (groups 5–10) and shows individual virus titres of blood
samples collected at different time points post-infection calculated by standard plaque assay. Each mouse is indicated by a different colour and symbol.
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Fig. 5. Passive immunisation and AHSV-4 challenge. VNAb responses (A) and
VP2-speciﬁc Igs responses measured by indirect ELISA (B). (A) Each bar represents
the geometric mean of VNAb titres of individual serum samples collected on day 0
(challenge day; black bars) and day 17 post-challenge (grey bars). Data was obtained
by microneutralisation test. The error bars denote the standard error within the
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Samples. (B) VP2 speciﬁc Igs response was measured by indirect ELISA using a 1:50
ilution of serum samples. Each dot represents a pool of sera of the group and the
esults are represented in OD values.
. Discussion
AHS is a lethal disease of horses transmitted by the same
ematophagous biting midges (Culicoides sp.) that transmit blue-
ongue virus, which causes a disease in ruminants that has spread
hrough Mediterranean and Central Europe in the last two decades.
he higher presence of insect vectors capable of transmitting AHSV
t the present time in Europe has increased the risk of another
utbreak. Current live attenuated AHSV vaccines have been used
ith relative success in Africa but there are concerns over their
iosafety in the ﬁeld. Killed vaccines have been used in the past,
hough on a limited scale (House et al., 1994; Ozawa and Bahrami,
966), and both attenuated and killed vaccines are incompatible
ith DIVA (differentiating infected from vaccinated animal) con-
rol strategies and therefore are regarded as inadequate for use in
on-endemic countries. This prompted the investigation of alterna-
ive vaccination strategies based mainly on the AHSV outer capsid
roteins VP2 and VP5 which are the target of VNAb (Burrage et al.,
993; Martinez-Torrecuadrada and Casal, 1995). These strategies
ncluded the use of baculovirus-expressed AHSV antigens, plas-
id  DNA vaccines and recombinant vaccinia virus vector vaccines
Romito et al., 1999; Roy et al., 1996; Stone-Marschat et al., 1996).
ome of these approaches have been successful in experimentalsearch 180 (2014) 23– 30 29
conditions but are not commercially viable whilst others have not
yet addressed important vaccination efﬁcacy issues such as dura-
tion of immunity or cross-protection.
The use of replication deﬁcient poxviruses expressing AHSV
capsid proteins has yielded promising results. Thus, a canarypox
virus expressing VP2 and VP5 of AHSV-4 protected horses against
homologous challenge (Guthrie et al., 2009). In addition, previous
studies in our laboratory showed that a recombinant MVA  express-
ing AHSV-VP2 stimulated high levels of neutralising antibodies
in ponies (Chiam et al., 2009) and provided protective immu-
nity in the IFNAR−/− mouse model (Castillo-Olivares et al., 2011).
These vaccination strategies are suited for differential diagnostics
(DIVA compatible) since they are based on one or two antigens of
AHSV.
Having demonstrated the capacity of MVA-VP2 to induce VNAb
in horses and VNAb and full protection against AHSV in a mouse
model (Castillo-Olivares et al., 2011), the primary objective of the
present study was to determine, in a passive immunisation exper-
iment, whether MVA-VP2 protection was  mediated by antibodies.
Thus, immunologically naïve mice received antisera from MVA-
VP2 vaccinated or from MVA-VP2 vaccinated and AHSV infected
mice and were then challenged with virulent AHSV and their pro-
tective immunity assessed. Our results showed that recipients
of MVA-VP2 vaccinated mouse antiserum (D2) were highly pro-
tected against clinical disease and death following AHSV challenge,
suggesting that MVA-VP2 vaccine induced immunity is mediated
primarily by antibodies. Passive immunisation was  less effective
when antiserum D2 was  diluted 1:10, and was  more effective in
mice that received D1 antiserum obtained from MVA-VP2 vacci-
nated and subsequently infected mice. Antibodies directed against
other AHSV proteins (D1 derived from MVA-VP2 vaccinated and
AHSV-4 infected mice), such as VP5, or even to more natural
forms of VP2, could have contributed to the slightly higher immu-
nity exhibited by the D1 recipients. It is known that VP5 exerts
some conformational effect on VNAb epitopes contained in VP2
(Martinez-Torrecuadrada et al., 1996). However, it is more likely
that the levels of VP2-speciﬁc VNAb of the donor antisera were
the main factors inﬂuencing the degree of protection observed in
the passively immunised mice, since protection levels decreased in
the following order: D1 recipients (VNAb titre 2.51), D2 recipients
(VNAb titre 1.95) and 1:10 diluted D2 recipients.
The passively immunised mice showed a lower degree of
viraemia despite being clinically protected, whereas the MVA-VP2
vaccinated mice were completely protected against both clini-
cal signs and viraemia. It is possible that cell-mediated immunity
played an additional protective role following MVA-VP2 vaccina-
tion. The capacity of recombinant MVA-based vaccines to induce
cellular immunity has been documented in the literature and
described before for BTV and AHSV (Calvo-Pinilla et al., 2012; Calvo-
Pinilla et al., 2009; de la Poza et al., 2013). In the present study we
observed that the level of IFN- producing CD8+ T-cells in MVA-
VP2 vaccinates was signiﬁcantly higher than in MVA-wt vaccinates
after in vitro stimulation with inactivated AHSV, indicating that
CD8+ T lymphocytes were primed in vivo by MVA-VP2. However,
the VNAb titres of MVA-VP2 vaccinates at the time of challenge
(2.00) were higher than those of the passively immunised mice,
considering the dilution effect of the administered volume of the
donor antisera (100 l) in the total blood volume of the recipients
(total blood volume of a 25 g mouse is 1.46 ml). This could probably
explain the higher protection observed in the MVA-VP2 vaccinates.
Further studies are necessary to discern whether MVA-VP2 vac-
cination induced immunity is exclusively mediated by antibodies
and to determine what is the speciﬁc the role of T cell responses in
protection, but here we have provided clear evidence that antibod-
ies induced by MVA-VP2 vaccination are highly protective against
AHSV infection. This suggests that MVA-VP2 vaccination induced
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ntiserum could potentially be used as an emergency treatment of
HSV infection in the target species. We  are currently exploring
his possibility.
In conclusion, our study showed that MVA-VP2 vaccination
nduces both antibody and cell-mediated immunity and that the
P2-speciﬁc, VNAb response induced by MVA-VP2 vaccination
lays a key role in the protection against AHSV.
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